Group 1 - The core viewpoint of the articles highlights the performance and valuation metrics of Guoji Medical, indicating a recent stock price increase and a notable market capitalization of 11.586 billion yuan [1] - As of March 31, 2025, Guoji Medical has 109,907 shareholders, an increase of 4,413 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in health care services and modern medical technology applications, with its main products spanning medical services, software and IT services, social services, and commodity circulation [1] Group 2 - The latest financial results for Q1 2025 show Guoji Medical achieved a revenue of 999.7 million yuan, a year-on-year decrease of 14.99%, and a net loss of approximately 106.35 million yuan, reflecting a year-on-year decline of 1.37% [1] - The company's gross profit margin stands at 5.21% [1] - In terms of valuation, Guoji Medical has a price-to-earnings (PE) ratio of -45.34 and a price-to-book (PB) ratio of 3.25, with a total market value of 11.586 billion yuan, compared to the industry average PE of 41.42 and PB of 3.52 [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of International Medical Investment Co., Ltd, indicating a decline in revenue and net profit in the latest quarterly report [1][2] - As of May 15, the company's stock closed at 5.2 yuan, down 1.33%, with a latest price-to-book ratio of 3.29 and a total market capitalization of 11.754 billion yuan [1] - The company experienced a net outflow of 6.0947 million yuan in principal funds on May 15, although it had a total inflow of 9.3634 million yuan over the past five days [1] Group 2 - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 999.7 million yuan, a year-on-year decrease of 14.99%, and a net profit of -106.35 million yuan, a year-on-year decrease of 1.37%, with a gross profit margin of 5.21% [1] - The company has received multiple honors, including being recognized as one of the "Top 100 Socially Operated Hospitals" and "Best Investor Relations Award" for 2024, indicating its reputation in the healthcare sector [1] - In comparison to industry averages, the company's price-to-earnings ratio (TTM) stands at -45.99, significantly lower than the industry average of 37.79, reflecting its current financial challenges [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of International Medical Investment Co., Ltd, including its recent stock performance and institutional holdings [1][2] - As of May 13, the stock price of International Medical closed at 5.29 yuan, with a 2.52% increase, and a market capitalization of 11.957 billion yuan [1] - The company reported a revenue of 999.7 million yuan for Q1 2025, reflecting a year-on-year decrease of 14.99%, and a net profit loss of approximately 106.35 million yuan, with a gross margin of 5.21% [1] Group 2 - The company has a price-to-earnings (PE) ratio of -46.79 (TTM) and a price-to-book (PB) ratio of 3.35, which is higher than the industry average PB of 3.42 [2] - International Medical is recognized for its contributions to the healthcare sector, receiving multiple awards, including being listed among the top 100 private hospitals in various categories [1] - The company is part of a competitive industry, with several peers showing varying PE ratios, indicating a challenging market environment [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of International Medical, indicating a decline in revenue and net profit in the latest quarterly report [1] - As of March 31, 2025, the number of shareholders for International Medical increased to 109,907, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company operates in the health care service sector and has received multiple accolades, including being recognized as one of the top 100 private hospitals in the 2024 benchmark hospital research [1] Group 2 - The latest financial results for the first quarter of 2025 show a revenue of 999.7 million yuan, representing a year-on-year decrease of 14.99%, and a net loss of approximately 106.35 million yuan, a decline of 1.37% year-on-year [1] - The company's current price-to-earnings (P/E) ratio is significantly negative at -45.28, compared to the industry average of 38.00, indicating a poor valuation relative to peers [2] - The market capitalization of International Medical stands at 11.573 billion yuan, with a price-to-book (P/B) ratio of 3.24, which is slightly below the industry median of 2.61 [2]

5月6日，国际医学今日收盘5.11元，上涨1.39%，最新市净率3.24，总市值115.51亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)7国际医学-45.20-45.453.24115.51亿行业平均 38.6644.753.42152.65亿行业中值38.3646.642.7251.49亿1润达医疗-313.36207.372.70114.63亿2何氏眼 科-135.21-117.661.6932.24亿3*ST生物-102.63-99.788.4319.80亿4普瑞眼科-71.97-64.663.0965.86亿5诚达 药业-67.32-115.331.5132.41亿6皓宸医疗-48.55-58.395.7622.01亿8创新医疗-40.51-45.232.4142.50亿9金域 医学-36.51-37.392.07142.54亿10百诚医药-29.56-72.171.4938.07亿11迪安诊断-22.95-25.781.4192.12亿 截至2025年一季报，共有10家机构持仓国际医学，其中其他5家、基金4家、券商1家，合计持股数 75944.78万股，持股市值41.39亿元。 来 ...